THE TEMPORAL HORMESIS OF DRUG THERAPIES by Dudekula, Noor et al.
Dose-Response: An International Journal
Volume 3 | Issue 4 Article 11
9-2005
THE TEMPORAL HORMESIS OF DRUG
THERAPIES
Noor Dudekula
University of Houston, Houston, TX
Vikas Arora
University of Houston, Houston, TX
Zsuzsanna Callaerts-Vegh
University of Houston, Houston, TX
Richard A Bond
University of Houston, Houston, TX
Follow this and additional works at: https://scholarworks.umass.edu/dose_response
This Article is brought to you for free and open access by ScholarWorks@UMass Amherst. It has been accepted for inclusion in Dose-Response: An
International Journal by an authorized editor of ScholarWorks@UMass Amherst. For more information, please contact
scholarworks@library.umass.edu.
Recommended Citation
Dudekula, Noor; Arora, Vikas; Callaerts-Vegh, Zsuzsanna; and Bond, Richard A (2005) "THE TEMPORAL HORMESIS OF DRUG
THERAPIES," Dose-Response: An International Journal: Vol. 3 : Iss. 4 , Article 11.
Available at: https://scholarworks.umass.edu/dose_response/vol3/iss4/11
Dose-Response, 3: 414–424, 2005
Formerly Nonlinearity in Biology, Toxicology, and Medicine
Copyright © 2005 University of Massachusetts
ISSN: 1540-1421
DOI: 10.2203/dose-response.003.03.009
414
THE TEMPORAL HORMESIS OF DRUG THERAPIES 
Noor Dudekula, Vikas Arora, Zsuzsanna Callaerts-Vegh, and Richard A. Bond
 Department of Pharmacological and Pharmaceutical Sciences, 
University of Houston, Houston, Texas
 Recent publications in the field of asthma therapeutics and studies performed over
the last decade in the treatment of chronic heart failure suggest a phenomenon called
‘temporal hormesis’. This phenomenon can be defined as the beneficial action of drug
after chronic administration as opposed to its detrimental acute effects. Temporal horme-
sis may be related to the classification of the drug molecule as an agonist, antagonist or an
inverse agonist. This phenomenon may be a more general principal applicable in the
treatment of other diseases apart from asthma and chronic heart failure. 
Keywords: Temporal hormesis, Beta-adrenoceptor antagonist, Chronic therapy, Asthma, Heart failure
SUMMARY
In the past decade a major paradigm shift has occurred in the treat-
ment of chronic heart failure, wherein some contraindicated drugs have
been shown to be beneficial in the disease treatment (Bond, 2002).
Furthermore, a recent paper from our laboratory suggests the possibility
of using a currently contraindicated drug for chronic asthma therapy
(Callaerts-Vegh et al., 2004). These drugs (β-adrenoceptor blockers) are
or have been contraindicated for asthma and CHF because when given
acutely they worsen the symptoms of the disease. Possibly because it was
assumed that the chronic effect would be similar to their acute effect, the
chronic effects of these drugs were never investigated until recently.
However, in both CHF and asthma chronic administration of the drugs
resulted in improvement in the hallmark symptoms of the disease. In
CHF the beneficial effect has been demonstrated both in animal models
(Asanuma et al., 2004) and human patients (Hall et al, 1995) whereas in
asthma it has been studied only in animal models (Callaerts-Vegh et al.,
2004). Also, both disease treatments involve a G protein-coupled receptor
(GPCR) termed the β2-adrenoceptor (β2AR). Evidence suggests that in
CHF and in our murine model of asthma only drugs classified as β2AR
inverse agonists are capable of producing the beneficial chronic effect.
The data from both heart failure and the asthma model studies suggests
that the duration of drug administration plays a major role in determin-
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ing its response (Bond, 2002 & Ellis, 2004). The beneficial action of the
drug after chronic administration as opposed to its detrimental acute
effects can be defined as temporal hormesis. This is different from classi-
cal hormesis, which is defined as the ‘dose-response phenomenon char-
acterized by low dose stimulation, high dose inhibition, resulting in either
a J-shaped or an inverted U-shaped dose response’ (Calabrese, 2004).
Hence, classical hormesis is defined by the dose of the drug as the main
criterion, while temporal hormesis can be defined relative to the duration
of therapy. Examples and possible explanations of the phenomenon of
temporal hormesis are discussed in more detail in the following sections.
BRIEF HISTORY OF INVERSE AGONISM 
AT G PROTEIN-COUPLED RECEPTORS 
GPCRs are the largest superfamily of receptors and also the target
molecules for almost two-thirds of the drugs on the market. In classical
receptor theory, only two classes of ligands were considered to interact
with receptors: agonist and antagonist. Receptors were believed to exist in
a single quiescent, non-signaling state. Only after agonist binding would
the activated receptor induce signaling. In this model, binding by antag-
onists produced no cellular signaling but simply prevented receptors
from being bound and activated by agonists. Then, Costa and Herz
demonstrated that receptors could be manipulated into a constitutive or
spontaneously active state that produced cellular signaling in the absence
of agonist occupation (Costa and Hertz, 1989). They also provided evi-
dence that certain compounds could ‘turn-off’ or inactivate these spon-
taneously active receptors. The authors termed these compounds ‘nega-
tive antagonists’. The term ‘negative antagonist’ has now been largely
replaced by the term ‘inverse agonist’. In the ensuing years, many studies
have provided further evidence that GPCRs exist in constitutively or spon-
taneously active states that are inactivated by inverse agonists [for reviews
see, (de Ligt et al., 2000 & Milligan et al., 1995)]. The β2AR is a prototype
GPCR for studying inverse agonism, the first in vivo report of constitutive
activity and inverse agonism was shown in β2AR (Samama et al., 1993;
Chidiac et al., 1994; Samama et al., 1994 & Bond et al., 1995).
ANTAGONISTS VERSUS INVERSE AGONISTS 
Inverse agonists are often viewed as a subset of antagonists because
under conditions of low numbers of spontaneously active receptors,
inverse agonists produce effects qualitatively similar to those of antago-
nists. However, it is important to differentiate the properties of antago-
nists from those of inverse agonists. In the two-state model, receptors exist
in equilibrium between an inactive state (R), and a spontaneously active
state (R*) (Milligan et al., 1995; Bond et al., 1995 & Leff, 1995). Agonists
preferentially bind to and enrich the number of receptors in the R* state
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and decrease the receptors in the R state. Inverse agonists preferentially
bind to and enrich the number of receptors in the inactive R state there-
by decreasing the numbers in the R* state. Antagonists bind with equal
affinity to both R and R* and do not change their numbers, but do pre-
vent both agonists and inverse agonists from producing their effects. 
Agonists and inverse agonists modulate cellular activity in a reciprocal
manner (Table 1). For example, inverse agonists move ‘baseline’ recep-
tor activity in a direction opposite to that produced by agonist. This ‘rec-
iprocity’ of agonists and inverse agonists seems to hold true for all param-
eters investigated so far. Furthermore, this reciprocity implies that inverse
agonists alter signaling on their own. Their effects are not solely attribut-
able to the prevention of agonist activity as would be true for antagonists.
For example, ligands now classified as inverse agonists can produce
upregulation of β2ARs after the depletion of agonists (Elfellah & Reid,
1989). It is possible that the reciprocity of agonists and inverse agonists
extends to their ability to modulate cellular signaling. Agonists given
acutely increase signaling by receptor activation and chronic agonist
treatment desensitizes and decreases signaling, this cellular signaling is
manifested in the organism as the physiological effects (hence, increased
signaling = increased effect/response and decreased signaling =
decreased effect/response). In contrast, inverse agonists acutely decrease
cellular signaling yet may be able to chronically increase signaling (high-
lighted box of Table 1). We believe it is this reciprocity that accounts for
the temporal hormesis observed with drug treatment of certain diseases
(Figure 3).
TABLE 1 Comparison of agonist and inverse agonist properties
Agonist Inverse agonist
Promotes formation of more active receptor (R*) Promotes formation of more inactive 
receptor (R)
Promotes receptor-G protein coupling Decreases receptor-G protein coupling
Promotes phosphorylation by GRK Prevents phosphorylation by GRK
Promotes endocytosis and downregulation of 
receptor
Promotes upregulation of cell surface 
receptors
Promotes conformational changes (decreases 
fluorescence emission)
Promotes conformational changes (increases 
fluorescence emission)
Homologous desensitization Homologous sensitization
Heterologous desensitization Heterologous sensitization
ACUTELY PROMOTES EFFECT ACUTELY INHIBITS EFFECT
CHRONICALLY INHIBITS EFFECT CHRONICALLY PROMOTES EFFECT
Both agonists and inverse agonists effects are blocked by antagonist (modified from Bond, et al.,
2001)
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BENEFICIAL EFFECTS OF CHRONIC TREATMENT WITH ‘β-BLOCKERS’ 
CHF is a major health concern associated with a high degree of mor-
tality. Recently, a major paradigm shift in the chronic treatment of CHF
has lead to the widespread clinical use of a previously contraindicated
class of drugs, ‘β-blockers’. In CHF there is a decrease in cardiac con-
tractility and the heart is unable to meet the blood and oxygen demands
of the body. The body responds to the diminished output by elevating the
levels of norepinephrine and epinephrine delivered to the heart. This
results in the chronic activation of the βAR system, eventually leading to
desensitization of the receptors and a decrease in the βAR density in the
heart (Bristow et al., 1982).
Since the failing heart shows a decreased contractility, positive inotrop-
ic agents are used to increases cyclic AMP levels to improve cardiac output.
The βAR agonists dobutamine and xamoterol increase myocardial con-
tractility and short-term administration of dobutamine results in an
improved cardiac performance (Weber et al., 1982; Stoner et al., 1977 &
Leier et al., 1977). However, placebo-controlled clinical trials reported an
increase in mortality among patients treated long term with intravenous
dobutamine (Weber et al., 1982 & Dies et al., 1986) and xamoterol (1990,
The Xamoterol in Severe Heart Failure Study Group). Therefore the use
of βAR agonists produces initial cardiac improvements, but long-term
administration results in loss of βAR function and a drop of cardiac func-
tion in failing hearts, and ultimately in an increased risk of mortality.
FIGURE 1 A schematic representing the fundamental hypothesis of temporal Hormesis, that ago-
nists and inverse agonists have temporally reciprocal effect on cellular signaling.
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The class of drugs termed ‘β-blockers’, is comprised of βAR antago-
nists and inverse agonists, and has been shown to have negative inotrop-
ic activity and produce decreases in cardiac output (Kukin et al., 1999).
Therefore treating a system with decreased contractility, such as heart fail-
FIGURE 2 The left ventricular ejection fraction was measured using Echocardiograph. Changes in the
left ventricular ejection fraction from baseline to day 1, month 1 and month 3 in the metoprolol and
standard therapy groups were recorded. The standard therapy was a long term angiotensin converting
enzyme inhibitor except in two patients who received isosorbide dinitrate/hydralazine. Ejection frac-
tion decreased about 25% on day 1 with acute metoprolol administration and increased only after 1
month of metoprolol therapy and by the 3rd month the metoprolol treated patients showed a signifi-
cant increase in the left ventricular ejection fraction. (Reprinted with permission from JACC)
FIGURE 3 Effects of administration of β-AR ligands on the peak airway responsiveness to cholinergic
stimulation. Peak Raw was determined for each mouse by examining the individual methacholine dose-
response curves and choosing the highest Raw value produced by any of the methacholine doses (most
often next to the last dose, 408 µg.kg–1.min–1). Shown are the mean peak Raw  SEM after treatments with
the β-AR agonist salbutamol (A) and after treatments with β-AR inverse agonist nadolol (B), after both
acute and chronic administration, in comparison with non treated asthmatic mice (NTX; black bars, n =
7−25) and control mice (Ctr; white bars, n = 6−21). Note the change in the scale of y axis for B. *, P ≤ 0.05
compared to NTX; #, P ≤ 0.05 compared to Ctr (ANOVA). (Reprinted with permission from PNAS)
(a) (b)
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ure, with β-blockers was contraindicated. However, studies have shown
that chronic treatment with certain ‘β-blockers’ can improve cardiac
function and decrease mortality (Lechat et al., 1998). Though initially this
treatment may be associated with a further decrease in cardiac output
and detrimental effects, chronic treatment over several months leads to a
significant improvement of cardiac function (Hall et al., 1995 & Packer et
al., 1996). Several long-term clinical trials have been conducted using the
‘β-blockers’ carvedilol (Packer, 1996) and metoprolol (Hjalmarson et al.,
2000 & MERIT-HF Study Group, 2000) each resulting in improved car-
diac function and decreased mortality (Krum, 1997). In contrast, a recent
large-scale trial with the ‘β-blocker’ bucindolol failed to show a significant
beneficial effect (β-blocker Evaluation of Survival trial Investigators,
2001). In summary, chronic treatment with certain ‘β-blockers’, has been
shown to decrease mortality and improve cardiac function, while bucin-
dolol produced no effect. 
IS THE INVERSE AGONISM OF ‘β-BLOCKERS’ 
THE REASON FOR THERAPEUTIC BENEFIT? 
The differential therapeutic effects of carvedilol, metoprolol and
bucindolol raise the question as to what distinguishes these compounds at
the mechanistic level. A recent study examined the antagonist or inverse
agonist properties of these three compounds. In cardiac myocytes from fail-
ing human hearts pretreated with forskolin to amplify any constitutive sig-
naling, metoprolol and carvedilol both functioned as inverse agonists,
while bucindolol behaved as an antagonist (Maack et al., 2000). Thus, both
compounds that are beneficial in the chronic treatment of heart failure
and have acute adverse effects are inverse agonists. In contrast, the com-
pound with no chronic benefits, bucindolol behaved as an antagonist.
Though this study did not examine which βAR subtype was involved in
mediating the inverse agonist effects of the compounds, it is likely to be the
β2-subtype for the following reasons: (1) Although metoprolol is classified
as a preferential or cardio selective β-blocker, its selectivity for β1AR overβ2AR is very poor and can be as low as 2 fold (Baker, 2005 & Flesch et al.,
2001). Thus at the concentrations normally used in heart failure, this lig-
and would also be occupying β2ARs. (2) Reduction in mortality was greater
in patients treated with non-selective as compared to selective β1AR block-
ing agents (Lechat et al., 1998). (3) β1ARs are downregulated in heart fail-
ure, while β2ARs are not (Brodde et al., 1992) resulting in an increase in theβ2/β1 ratio. Several studies have shown that the β2AR exhibits more spon-
taneous activity than the β1AR. For example, mice with cardiac overexpres-
sion of the β2AR exhibit greater increases in cardiac contractility than mice
overexpressing the β1AR (Engelhardt et al., 1999 & Milano et al., 1994). (4)
In a murine coronary artery occlusion model of heart failure, we have
observed beneficial effects of an inverse agonist (carvedilol) but not an
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antagonist (alprenolol) suggesting the murine model behaves similarly
(Callaerts-Vegh et al., 2004). In summary, currently available data all indi-
cate that chronic treatment with inverse agonists is beneficial in a disease
state characterized by impaired βAR signaling.
ASTHMA, SIMILAR DRUGS, OUTCOMES AND RECEPTORS: 
PARADIGM SHIFT? 
Asthma affects an estimated 20 million Americans and its incidence is
increasing. Although diagnosis and medications have improved the man-
agement of asthma, the age adjusted mortality rate increased 55.6%
between 1979 and 1998 (American Lung Association: Epidemiology and
Statistics Unit, 2004). The increased incidence and mortality clearly asks
for a better understanding of the physiology and pharmacology underly-
ing the asthma disease state. Interestingly, asthma and CHF display sig-
nificant similarities in their pharmacology. 
Acute treatment with βAR agonists is beneficial in both diseases yet
chronic treatment can be detrimental. For example, β2AR agonists
induce bronchodilation, and are the most commonly used drugs for
treatment of asthma. A clinical trial testing the chronic use by asthmatics
of a long lasting β2AR agonist, salmeterol, was recently terminated due to
increased deaths in some patient groups (FDA, 2003), similarly chronic
use of βAR agonists has been reported to increase mortality in heart fail-
ure patients (Packer, 1995). The detrimental effect of chronic βAR ago-
nist treatment has also been demonstrated in animal models of asthma
(Hoshiko & Morley, 1993 & Mazzoni et al., 1994). It was shown recently
that modest overexpression of the human β2AR in transgenic mice
increased the airway response to spasmogens via an upregulation of phos-
pholipase C-β1 (McGraw et al., 2003). Conversely, knocking out β1 and β2-
ARs led to a decrease in airway response to spasmogens. The authors
termed the phenomena ‘antithetical regulation’ and suggested their
results warrant testing of ‘β-blockers’ in asthma. While the mortality issue
due to chronic agonist use in asthmatics is multifactorial, one of the risk
factors for death from asthma is the excess use of inhaled β2AR agonists
(Spitzer et al., 1992 & National Asthma Education and Prevention
Program, 1997). 
Conversely, acute treatment with βAR inverse agonists is detrimental
for both CHF and asthma patients. βAR inverse agonists can acutely result
in bronchoconstriction and are currently contraindicated in asthmatics
(Hua et al., 1978). Asthma patients may experience severe airway nar-
rowing after an acute dose of β-blocker, similar to the initial reduction in
left ventricular ejection fraction (an index of cardiac contractility), in
CHF patients. Thus, there are remarkable similarities between the phar-
macological modulation of the β2AR in both CHF and asthma.
Nevertheless, aside from our recent study (Callaerts-Vegh et al., 2004) the
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effect of chronic treatment with βAR antagonists or inverse agonists in
asthma has not been tested. Although asthma and heart failure are dif-
ferent diseases, very similar ligands are being used in their treatment; the
ligands act at the same receptor systems, and produce similar outcomes,
i.e. acutely detrimental and chronically beneficial.
β-ADRENOCEPTOR LIGANDS AND ASTHMA
We administered the β2AR agonist salbutamol and the inverse agonist
nadolol acutely and chronically to study their effects on the airway
responsiveness in a murine model of asthma. When the drugs were
administered acutely, we observed the classical response of the β-adreno-
ceptor agonists in asthma therapy. Salbutamol effectively reduced airway
resistance by causing bronchodilation, while nadolol worsened the symp-
tom triggering exaggerated bronchoconstrictor response (Figure 3a &
3b), which is in accordance with previously published data (Boskabady &
Snashall, 2000). This exaggerated bronchial response of airways on acute
β-blocker administration is responsible for this drug class to be con-
traindicated in asthma therapy. 
However, some of the chronic results were not as expected. As has
been reported in earlier studies, we also observed a loss in response to the
agonist salbutamol with chronic therapy, wherein the airway response to
methacholine was similar to that of an untreated asthmatic mouse
(Figure 3a) (Tamaoki et al., 2004). However, chronic treatment with
nadolol had an opposite response compared to nadolol administered
acutely. Chronic treatment with nadolol produced significantly reduced
airway responsiveness (Figure 3b). This supports our hypothesis that
given chronically, some β-adrenoceptor antagonists/inverse agonists may
effectively alleviate the symptoms of asthma. The mechanism by which
this beneficial effect occurs is still not clear but may involve an increase
in β-adrenoceptor number in the airways of the animals treated chroni-
cally with nadolol (Callaerts-Vegh et al., 2004).
These studies suggests that treatment with some β-blockers may be
useful in asthma therapy, but a major concern of using these drugs in
patients would be the bronchoconstrictor response observed when the
drug is administered initially. Ways to avoid this unwanted effect of the
drug could be by starting with a very low dose of the antagonist, as is done
in heart failure treatment, and then increasing the dose over a period of
time, or the blocker can initially be given in combination with an agonist
to reduce the unwanted response in patients. While there is always risk in
extrapolating from mice to men, this study may provide another example
of the temporal hormesis observed with some drug therapies.
8
Dose-Response: An International Journal, Vol. 3 [2014], Iss. 4, Art. 11
https://scholarworks.umass.edu/dose_response/vol3/iss4/11
N. Dudekula et al.
422
IS TEMPORAL HORMESIS AN ISOLATED INCIDENT 
OR A GENERAL PHENOMENON?
Both the above examples clearly show opposing effects of drugs
depending on the duration of therapy. The agonist and the
antagonist/inverse agonist produce opposite responses dependent upon
whether given acutely or chronically. To assume that this phenomenon of
temporal hormesis is an isolated incident seen only in heart failure or
asthma (since both involve β-adrenoceptors) may be presumptuous. A
good example of the temporal hormesis is in pain management. Upon
chronic administration of morphine (an opioid agonist), tolerance devel-
ops to its analgesic effect. Crain and Shen, in 1998, reviewed the literature
showing that chronic administration of morphine with an opioid antago-
nist/inverse agonist (such as naltrexone) was more effective in pain man-
agement then morphine alone (Crain & Shen, 1998). They speculated
this enhancement in morphine activity in conjunction with naltrexone
was due to the antagonist preventing the morphine-induced tolerance.
These authors helped to form a company, Pain Therapeutics, which now
has a combination product of opioid agonist and antagonist/inverse ago-
nist in Phase III trials. There are also other diseases in which patients
become refractory to chronic agonist treatment. For example, many stud-
ies have shown a loss of response in Parkinson’s patients treated chroni-
cally with dopamine agonists (Gerlach & Riederer, 2003). All of the above
diseases involve receptors that belong to the superfamily of G protein-
coupled receptors (GPCRs). These receptors are often regulated by relat-
ed kinases involved in desensitization; therefore, it is possible that these
diseases could also be treated with either blockers or the combination of
agonist and blocker. Temporal hormesis may turn out to be a general
phenomenon of GPCRs, at least in cases where the agonist loses effec-
tiveness when administered over a long period of time. 
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